Mpox Booster Doses Discouraged by the U.S. CDC

According to the U.S. CDC's MMWR 73(20);460–466, JYNNEOS® (MVA-BN®, IMVAMUNE®) vaccination does prevent mpox; however, infection in fully vaccinated persons can occur.

On May 23, 2024, the CDC disclosed that mpox virus infection after receipt of two JYNNEOS doses is estimated to have occurred in <1% of fully vaccinated persons.

Among persons who experienced infection after having received a complete 2-dose series and for whom complete data were available, mpox infections have been milder than those among unvaccinated persons.

In 2024, mpox cases have been reported in urban centers such as New York City, which confirmed 42 mpox cases from April 7, 2024, to May 4, 2024.

The CDC says that to optimize protection, persons recommended to receive mpox vaccination should complete Bavarian Nordic's JYNNEOS vaccination series. Estimates suggest that about two million U.S. individuals are eligible for mpox vaccination.

Furthermore, the CDC does not recommend additional vaccine doses at this time.

Regarding the current clade 1 mpox outbreak in Africa, on March 14, 2024, Agam Rao, MD CAPT, US Public Health Service, stated, 'JYNNEOS vaccination is expected to be effective regardless of mpox clade.